Results 61 to 70 of about 75,218 (96)

Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. [PDF]

Diabetes Metab Res Rev
Lee N, Kim Y.
europepmc   +1 more source

Body Contouring in the Era of GLP-1 Therapy: Are We Ignoring Tissue Biology? [PDF]

Plast Surg (Oakv)
Tomaselli F, Albanese R, Tambasco D.
europepmc   +1 more source

GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease. [PDF]

Int J Mol Sci
Gandhi A, Phyu EM, Koom-Dadzie K, Dickson KB, Halm J.   +4 more
europepmc   +1 more source

A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists. [PDF]

J Clin Med
Virk A, Allison K.
europepmc   +1 more source

Reply: Time-Related Biases in Observational Studies of GLP-1 Agonists and Cancer Risk. [PDF]

J Diabetes
Cheng Z, Lin J, Gu D, Liang F.
europepmc   +1 more source

GLP-1 guidelines amid an obesity epidemic: a poor fit for the Global South. [PDF]

Arch Public Health
Shrisunder R, Karmarkar V.
europepmc   +1 more source

A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity. [PDF]

Healthcare (Basel)
Lee AH, Holmes-Walker DJ.
europepmc   +1 more source

GLP-1 Receptor Agonists and Noncardiometabolic Outcomes: An Umbrella Review of Meta-Analyses.

JAMA Netw Open
Yang K, Liu C, Guo Q, Li Y.
europepmc   +1 more source

GLP-1 physiology and pharmacology along the gut-brain axis. [PDF]

J Clin Invest
Beutler LR.
europepmc   +1 more source